Fortress Biotech（FBIO）株式概要
Fortress Biotech, Inc.は、その子会社とともに、米国内外でバイオ医薬品会社として事業を展開している。 詳細
FBIO Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fortress Biotech, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$2.74 |
| 52週高値 | US$4.53 |
| 52週安値 | US$1.69 |
| ベータ | 1.16 |
| 1ヶ月の変化 | 21.78% |
| 3ヶ月変化 | -18.45% |
| 1年変化 | 53.93% |
| 3年間の変化 | -66.73% |
| 5年間の変化 | -95.47% |
| IPOからの変化 | -98.34% |
最新ニュース
Recent updates
ナラティブの更新 • May 12
FBIO: Rare Pediatric Disease Voucher Will Support Future Upside Potential
Analysts have lifted their Fortress Biotech price target to $4.50 from $4.50, supported by updated assumptions around a slightly lower discount rate, adjusted revenue growth, an improved profit margin outlook, and a reduced future P/E multiple. Valuation Changes Fair Value: $4.50 is unchanged, with the target level held steady versus prior estimates.ナラティブの更新 • Apr 25
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around a fair value of $4.50, a discount rate of 8.80%, revenue growth of 44.56%, a profit margin of 12.79% and a future P/E of 9.24. Valuation Changes Fair Value: Maintained at $4.50, with no change in the estimated fair value per share.ナラティブの更新 • Apr 11
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to reflect updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. This has led to a revised target that is intended to better align with the company’s current risk and earnings outlook.ナラティブの更新 • Mar 27
FBIO: Menkes Disease Breakthrough And Voucher Will Drive Future Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the overall fair value view steady. What's in the News FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, marking the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).ナラティブの更新 • Mar 12
FBIO: Menkes Disease Approval And Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech, maintaining it at $4.50, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions that continue to support a similar fair value estimate. What's in the News Fortress Biotech and majority owned subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO (copper histidinate, formerly CUTX-101) to treat Menkes disease in pediatric patients, the first and only FDA approved treatment for this rare and often fatal condition (Key Developments).ナラティブの更新 • Feb 26
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Support Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech, reflecting updated views on revenue growth, profit margins, and future P/E assumptions, while keeping the underlying fair value estimate steady at $4.50. What's in the News The U.S. FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients.Seeking Alpha • Feb 20
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
Summary Fortress Biotech is essentially a holding company biotech with a dermatology revenue base (Journey Medical). However, FBIO’s subsidiaries give it optionality across multiple subsidiaries, equity stakes, and royalty streams. FBIO’s Journey Medical assets give it its branded dermatology portfolio. The newly approved Emrosi provides near-term revenues. But more importantly, Zycubo (CUTX-101) for Menkes disease was FDA-approved in January 2026. This created a Rare Pediatric Disease PRV for FBIO. PRVs can be extremely valuable, and given FBIO’s microcap status, it could be a major upside catalyst if they sell it at a good price. Read the full article on Seeking Alphaナラティブの更新 • Feb 11
FBIO: Menkes Disease Approval And Voucher Potential Will Drive Bullish Upside
Analysts have nudged their price target on Fortress Biotech higher to $4.50, reflecting updated assumptions around revenue growth, profit margins, and a slightly lower discount rate that together indicate a modestly stronger outlook for the company. What's in the News The U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).分析記事 • Feb 05
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares have retraced a considerable 28% in the last month, reversing a fair...ナラティブの更新 • Jan 28
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Drive Bullish Outlook
Analysts have adjusted their price target on Fortress Biotech, reflecting updated assumptions on a discount rate, a profit margin of 65.99% and a future P/E of 1.53x. They are tying the change to a revised view of the company’s earnings power and risk profile.ナラティブの更新 • Jan 12
FBIO: Resubmitted Menkes Therapy And Voucher Potential Will Shape Balanced Outlook
Analysts have adjusted their price target on Fortress Biotech to US$4.50, with the update mainly tied to refreshed assumptions around the discount rate, revenue growth near 48.3%, profit margin around 16.2% and a future P/E of about 6.17x. What's in the News Fortress Biotech and majority-owned subsidiary Cyprium Therapeutics had the resubmission of the New Drug Application for CUTX-101, a copper histidinate therapy for pediatric Menkes disease, accepted by the U.S. FDA as a Class 1 resubmission, with a new PDUFA target action date of January 14, 2026 (company announcement).ナラティブの更新 • Dec 26
FBIO: FDA Progress On Rare Disease Therapy Will Drive Significant Upside Potential
Analysts have modestly lifted their price target on Fortress Biotech to $4.50 per share, citing slightly lower perceived risk, marginally stronger long term revenue growth, and a small improvement in projected profitability that together support a higher justified valuation multiple. What's in the News FDA accepts resubmission of the New Drug Application for CUTX-101 for Menkes disease as a Class 1 resubmission, setting a new PDUFA target action date of January 14, 2026 (Key Developments) Earlier FDA Complete Response Letter for CUTX-101 cited cGMP compliance issues at the manufacturing site but raised no concerns with the drug's efficacy or safety data (Key Developments) Sentynl Therapeutics now holds full responsibility for development and commercialization of CUTX-101, with Cyprium eligible for royalties, up to $129 million in milestones, and a potential Rare Pediatric Disease Priority Review Voucher upon approval (Key Developments) CUTX-101 NDA, initially granted Priority Review, is supported by positive topline data showing significant improvement in overall survival in Menkes disease patients treated early (Key Developments) Valuation Changes Fair Value: unchanged at $4.50 per share, reflecting a stable central valuation despite minor model adjustments Discount Rate: decreased slightly from 8.36 percent to 8.07 percent, indicating a modest reduction in perceived risk Revenue Growth: increased slightly from 46.90 percent to 47.54 percent, reflecting marginally stronger long term growth expectations Net Profit Margin: increased slightly from 16.03 percent to 16.24 percent, pointing to a small improvement in projected profitability Future P/E: declined modestly from 6.51x to 6.29x, suggesting a slightly lower multiple applied to future earnings分析記事 • Dec 16
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 27% in...ナラティブの更新 • Dec 12
FBIO: Menkes Drug Clearance Of Manufacturing Issues Will Unlock Significant Upside Potential
Analysts have modestly raised their price target on Fortress Biotech to reflect a slightly higher fair value estimate of $4.50 per share, supported by expectations for stronger revenue growth and only a modest adjustment to discount rates and future valuation multiples. What's in the News The FDA issued a Complete Response Letter for the CUTX-101 New Drug Application for Menkes disease, citing cGMP deficiencies at the manufacturing facility but raising no concerns about efficacy or safety data.分析記事 • Oct 05
Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive
The Fortress Biotech, Inc. ( NASDAQ:FBIO ) share price has softened a substantial 26% over the previous 30 days...
ナラティブの更新 • Aug 19
FDA Approval Will Open $1 Billion Dermatology Market
Despite increased revenue growth forecasts, Fortress Biotech’s consensus price target was lowered from $10.00 to $8.00 amid a sharply reduced future P/E, indicating a more cautious outlook on profitability relative to anticipated sales growth. What's in the News Fortress Biotech was dropped from the Russell Microcap Growth Benchmark Index.分析記事 • Aug 17
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
With a price-to-sales (or "P/S") ratio of 1.1x Fortress Biotech, Inc. ( NASDAQ:FBIO ) may be sending very bullish...新しいナラティブ • Jul 06
FDA Approval Will Open $1 Billion Dermatology Market
Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.分析記事 • Mar 11
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...分析記事 • Oct 29
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Those holding Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares would be relieved that the share price has rebounded 36% in...分析記事 • Jul 26
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders have had their patience rewarded with a 54% share price jump in the...分析記事 • Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 99% in...分析記事 • Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy...株主還元
| FBIO | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 13.7% | -1.6% | -0.8% |
| 1Y | 53.9% | 34.4% | 27.1% |
業界別リターン: FBIO過去 1 年間で34.4 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: FBIO過去 1 年間で27.1 % の収益を上げたUS市場を上回りました。
価格変動
| FBIO volatility | |
|---|---|
| FBIO Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: FBIO 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: FBIOの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2006 | 78 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc.は、その子会社とともに、米国および海外でバイオ医薬品会社として事業を展開している。同社は、酒さ治療薬の塩酸ミノサイクリン徐放性カプセル「エムロシ」、腋窩多汗症治療薬の薬用クロスタオル「Qbrexza」を提供している；アキュテイン：重度の難治性結節性ざ瘡治療用の経口イソトレチノイン製剤；アムジーク：非結節性中等度から重度の尋常性ざ瘡の病変治療用のミノサイクリン外用フォーム剤；ジルシ：酒さの病変治療用のミノサイクリン外用フォーム剤；外用抗真菌クリーム「Exelderm」、重症にきび治療用経口ドキシサイクリン製剤「Targadox」、表在性創傷、軽度の切り傷または擦り傷、皮膚潰瘍、ドナー部位、第1度および第2度の熱傷、放射線皮膚炎治療用水性乳剤「Luxamend」、転移性皮膚扁平上皮がん治療用デスリガンド1遮断抗体「UNLOXCYT」。また、メンケス病治療薬としてFDA承認段階にあるヒスチジン酸銅注射剤CUTX-101、術後急性疼痛治療薬としてNDA/BLA申請段階にある静注用製剤Tramadol、痛風および慢性腎臓病治療薬としてフェーズIII段階にある尿酸トランスポーター阻害剤Dotinuradも開発している；アミロイド軽鎖アミロイドーシス治療薬としてフェーズⅢ段階にある軽鎖線維反応性モノクローナル抗体CAEL-101、サイトメガロウイルス、抗ヒト免疫不全ウイルス、非ホジキンリンパ腫、急性リンパ芽球性白血病治療薬としてフェーズⅡ段階にある万能組換えワクシニア・アンカラウイルスベクターワクチンTriplex。同社は以前はコロナド・バイオサイエンシズ社として知られていたが、2015年4月にフォートレス・バイオテック社に社名を変更した。Fortress Biotech, Inc.は2006年に法人化され、フロリダ州ベイハーバーアイランドを拠点としている。
Fortress Biotech, Inc. 基礎のまとめ
| FBIO 基礎統計学 | |
|---|---|
| 時価総額 | US$92.35m |
| 収益（TTM） | US$119.20m |
| 売上高(TTM) | US$66.16m |
0.8x
PER（株価収益率1.4x
P/SレシオFBIO は割高か？
公正価値と評価分析を参照収益と収入
| FBIO 損益計算書（TTM） | |
|---|---|
| 収益 | US$66.16m |
| 売上原価 | US$34.25m |
| 売上総利益 | US$31.91m |
| その他の費用 | -US$87.29m |
| 収益 | US$119.20m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 3.59 |
| グロス・マージン | 48.23% |
| 純利益率 | 180.16% |
| 有利子負債／自己資本比率 | 19.5% |
FBIO の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 02:03 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Fortress Biotech, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |